Second-generation Modular Acetabular Components Provide Fixation at 10 to 16 Years

Chapel Hill Orthopedics Surgery and Sports Medicine, 101 Conner Drive, Suite 200, Chapel Hill, NC 27514, USA.
Clinical Orthopaedics and Related Research (Impact Factor: 2.77). 06/2011; 470(2):366-72. DOI: 10.1007/s11999-011-1950-7
Source: PubMed


First-generation modular titanium fiber-metal-coated acetabular components had high rates of wear, pelvic osteolysis, and liner dissociation. Second-generation components were designed to reduce the incidence of these problems but it is unclear whether the changes achieved these goals.
We asked the following questions: (1) Is the risk of revision surgery for loosening, wear, or liner dissociation low with the second-generation acetabular component? (2) Is the rate of pelvic osteolysis low? (3) Can the liner be exchanged without bone cement?
We retrospectively reviewed prospectively collected data from 99 patients (118 hips) undergoing THAs with one second-generation modular titanium acetabular component with routine screw fixation and conventional polyethylene. The minimum followup was 10 years (mean, 12 years; range, 10-16 years). We obtained Harris hip scores and examined radiographs for loosening and osteolysis.
At last followup, all acetabular components were well fixed and no titanium shell had been revised or removed. No liner had dissociation. At most recent followup, the mean Harris hip score was 89. We observed pelvic osteolysis in eight hips (7%). There were three reoperations for dislocation (head-liner exchange only) and three loose femoral components revised. Two liners (at 11 and 14 years) were exchanged for wear-pelvic osteolysis.
This second-generation modular titanium fiber-metal-coated acetabular component with screw fixation had no loosening, no liner dissociation, and a low rate of pelvic osteolysis at 10 to 16 years. Liner exchange is practical without use of cement. We continue to use this component with highly crosslinked polyethylene liners.
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Managing blood loss in total hip arthroplasty (THA) minimizes complications and decreases cost. Tissue-sparing anterior supine intermuscular THA (ASI-THA) may offer a quicker recovery but increases blood loss and transfusion requirements. This double-blinded prospective study compared a bipolar sealer (Aquamantys 6.0 bipolar sealer) to standard monopolar electrocautery in reducing blood loss in ASI-THA. Differences in calculated actual blood loss (ABL), hemoglobin, and transfusion requirements were examined. One hundred hips were randomized to each group. Transfusion rates were similar, 6% and 4%, respectively (p>0.05). ABL and change in hemoglobin were identical (1.35 and 3.3g). No significant differences in transfusion, blood loss, or hemoglobin were seen with a bipolar sealer device. Routine use of this bipolar sealer device has been discontinued in ASI-THA.
    The Journal of arthroplasty 03/2013; 28(9). DOI:10.1016/j.arth.2013.01.032 · 2.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The purpose of this study was to evaluate the long-term clinical and radiographic outcomes of the Balgrist total hip replacement cup. Methods: We report the results of a retrospective review of 195 total hip prostheses with Balgrist cup implanted in 178 patients. There were 59 men and 119 women with a mean age at surgery of 52.3 years (range, 19-72). Cox regression was used to determine the influence of independent variables on the survivorship of the prosthesis. Results: There were 117 (66 %) of 178 patients, and 131 (67 %) of 195 hips available for assessment at a mean follow-up of 17.4 years. A total of 21 patients (22 hips) were lost from follow-up (12 %). A total of 25 patients (27 hips) required some type of re-operation during the follow-up period. Eight of 27 re-operations (30 %) were directly caused by the Balgrist cup failure due to fatigue fracture of the metallic shell (n = 5; 19 %), polyethylene wear (n = 2; 7 %) and aseptic loosening (n = 1; 4 %). The mean polyethylene wear rate was 0.068 mm/year (range, 0.008-0.230; SD = 0.043). The risk of re-operation for any reason was decreased with dysplastic hip as a primary diagnosis (hazard ratio; HR = 0.250; 95 % CI 0.086-0.725) and with greater age at the time of surgery (HR = 0.923; 95 % CI 0.880-0.969). The 19-year survivorship with re-operation for any reason was 75.6 % (95 % CI 67.0-84.2). The 19-year survivorship with re-operation for the Balgrist cup failure was 90.5 % (95 % CI 83.4-97.6). Conclusions: The Balgrist cup continues to provide excellent clinical and radiological outcomes. This is associated at least in part with a low polyethylene wear rate. The main reason for the Balgrist cup failure is fatigue fracture of the metallic shell.
    International Orthopaedics 06/2013; 37(8). DOI:10.1007/s00264-013-1946-x · 2.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Implant osseointegration is critical for achieving long-term stability of implants in acetabular revision, especially in the setting of severe bone loss. Porous trabecular metal (TM) augments provide a viable solution to deal with severe acetabular bone loss. We followed 93 hips in 83 patients using TM augments. The average age at the time of surgery was 67.5 years, average follow-up was 64.8 months. There were 2 Paprosky Type-IIA, 19 Paprosky Type-IIB, 15 Paprosky Type-IIC, 31 Paprosky Type-IIIA, 25 Paprosky Type-IIIB, and 1 Paprosky Type-IIIC defects. Kaplan-Meier rates of survival at 10 years were 98.9% and 96.8% using acetabular revision for aseptic loosening and revision for any reason as the endpoint, respectively. Three complications (3.23%) occurred in patients with underlying Paprosky Type-IIIB defects. These include 1 posterior dislocation, 1 heterotrophic ossification, and 1 aseptic loosening. While we report excellent mid-to-long term results using TM augments, longer follow-up studies are needed.
    The Journal of arthroplasty 03/2014; DOI:10.1016/j.arth.2014.03.016 · 2.67 Impact Factor
Show more


4 Reads
Available from